Muramyl dipeptide inhibits replication of human immunodeficiency virus in vitro.
In the search for compounds capable of inducing endogenous production of colony-stimulating factor (CSF) and possessing activity against human immunodeficiency virus (HIV), an immunomodulator, muramyl dipeptide (MDP), was investigated. MDP can enhance monocyte-macrophage CSF in serum and promote nonspecific resistance against a variety of microbial pathogens. MDP exhibited an inhibitory activity against HIV infection of CD4+ H9 lymphocytes and U937 monocytoid cells. An inhibitor of viral reverse transcriptase, 2', 3'-dideoxyadenosine, produced potent inhibition in cultures which were similarly infected with HIV. MDP could partially reduce antigen production in persistently HIV-infected KE37/1 lymphocyte cultures.
Masihi
K N
KN
Robert Koch Institute, Federal Health Office, West Berlin, Germany.
Lange
W
W
Rohde-Schulz
B
B
Chedid
L
L
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000494:pharmacology*; D002478:Cells, Cultured; D003115:Colony-Stimulating Factors / Q000096:biosynthesis; D016048:Dideoxyadenosine / Q000494:pharmacology; D015683:Gene Products, gag / Q000096:biosynthesis; D006678:HIV / Q000187:drug effects* / Q000254:growth & development; D016655:HIV Core Protein p24; D006801:Humans; D014758:Viral Core Proteins / Q000096:biosynthesis; D014779:Virus Replication / Q000187:drug effects*
D003115:Colony-Stimulating Factors; D015683:Gene Products, gag; D016655:HIV Core Protein p24; D014758:Viral Core Proteins; D016048:Dideoxyadenosine; D000119:Acetylmuramyl-Alanyl-Isoglutamine